AbbVie

ABBV

Market cap $388B

AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AbbVie said on Wednesday it is seeking to expand its presence in the fast-growing market for obesity treatments, leaning on the weight-loss drug it licensed last year from Danish biotech Gubra.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.

CNBC's Andrew Ross Sorkin reports on the latest news.

The pharma company has agreed to cut some prices in exchange for an exemption from some levies.

As part of the three-year deal, the Trump administration exempted AbbVie from tariffs and future pricing mandates, the company said.